The prescription for influencing drug pricing policy
MAY 7, 2026 The pharmaceutical industry increased its lobbying expenditures by 15% in 2025, but the companies anchoring the president's new prescription drug pricing program saw their spending jump by 8 additional percentage points while the plan was coming together. Also this week: A breakdown of the top fundraisers among House candidates and our interview with Tennessee's top campaign finance official. Drug companies involved in TrumpRx boosted lobbying by 23% ahead of program’s launch The 17 pharmaceutical companies anchoring TrumpRx, the White House’s new prescription drug-pricing program, poured more than $130 million into federal lobbying in 2025 – a nearly 23% surge that outpaced the broader industry as the plan was being shaped behind the scenes. Those companies accounted for more than a quarter of the record $457.3 million spent on lobbying last year across the pharmaceutical and health product industry . And while newly filed 2026 first-quarter reports show ...